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Abstract
Background: The IL-4 receptor a (IL-4Ra) chain has a broad expression pattern and participates in IL-4 and IL-13
signaling, allowing it to influence several pathological components of allergic lung inflammation. We previously
reported that IL-4Ra expression on both bone marrow-derived and non-bone marrow-derived cells contributed to
the severity of allergic lung inflammation. There was a correlation between the number of macrophages
expressing the IL-4Ra, CD11b, and IA
d, and the degree of eosinophilia in ovalbumin challenged mice. The
engagement of the IL-4Ra by IL-4 or IL-13 is able to stimulate the alternative activation of macrophages (AAM).
The presence of AAM has been correlated with inflammatory responses to parasites and allergens. Therefore, we
hypothesized that IL-4Ra
+ AAM play an active role in allergic lung inflammation. To directly determine the role of
AAM in allergic lung inflammation, M-CSF-dependent macrophages (BMM) were prepared from the bone-marrow
of IL-4Ra positive and negative mice and transferred to IL-4RaxRAG2
-/- mice. Wild type TH2 cells were provided
exogenously.
Results: Mice receiving IL-4Ra
+/+ BMM showed a marked increase in the recruitment of eosinophils to the lung
after challenge with ovalbumin as compared to mice receiving IL-4Ra
-/- BMM. As expected, the eosinophilic
inflammation was dependent on the presence of TH2 cells. Furthermore, we observed an increase in cells
expressing F4/80 and Mac3, and the AAM marker YM1/2 in the lungs of mice receiving IL-4Ra
+/+ BMM. The BAL
fluid from these mice contained elevated levels of eotaxin-1, RANTES, and CCL2.
Conclusions: These results demonstrate that transfer of IL-4Ra + macrophages is sufficient to enhance TH2-driven,
allergic inflammation. They further show that stimulation of macrophages through IL-4Ra leads to their alternative
activation and positive contribution to the TH2-driven allergic inflammatory response in the lung. Since an increase
in AAM and their products has been observed in patients with asthma exacerbations, these results suggest that
AAM may be targeted to alleviate exacerbations.
Background
Asthma is an inflammatory disease of the lung that has
increased dramatically in western countries over the
past 50 years [1-3]. Asthma is characterized by airway
hyperresponsiveness (AHR), mucus hypersecretion, and
airflow obstruction. Airways of asthmatics exhibit
chronic inflammation with infiltration of the bronchial
mucosa by lymphocytes, eosinophils, macrophages, and
mast cells in conjunction with epithelial desquamation,
goblet cell hyperplasia, and submucosal thickening. A
number of genetically modified mouse strains have been
used to understand the development of allergic inflam-
mation in response to the model allergen ovalbumin
[4-12]. T-cell deficient mice fail to develop lung inflam-
mation and AHR, while B-cell deficient mice (and there-
fore IgE deficient) and mast cell deficient mice still
develop these responses [5]. The importance of TH2
cells in the development of asthma in this model has
been well established [13]. Treatment of mice with anti-
IL-4, anti-IL-4Ra antibodies, or soluble IL-4Ra, inhibits
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expected, IL-4Ra
-/- mice and STAT6
-/- mice also have
greatly reduced asthma like symptoms in response to
allergen challenge [5-11].
In the previous studies, TH2 differentiation was
impaired explaining the lack of allergic inflammation.
However, several groups showed that IL-4Ra
-/- mice have
greatly reduced asthma like symptoms, even when purified
TH2 cells were provided exogenously [7,8]. In addition,
activating the receptor by transgenic expression or direct
administration of IL-4 or IL-13 into the lungs in the
absence of lymphocytes elicited symptoms of asthma
including eosinophilia, mucus production, and AHR
[7,14,15]. These results suggested that IL-4Ra on cells
other than T cells are important in the development of
asthma pathology. Using a bone-marrow chimera
approach, we previously showed that the expression of the
IL-4Ra chain on both bone marrow-derived and non-
bone marrow-derived cells contributes to disease progres-
sion [16]. While expression of the IL-4Ra chain on either
bone marrow- or non-bone marrow-derived cell types
supported eosinophilic infiltration, expression of the IL-
4Ra on both cell types resulted in the most severe inflam-
mation [16]. Phenotypic analysis showed a strong correla-
tion between the severity of allergic lung inflammation
and the presence of IL-4Ra
+ macrophages [16].
In the presence of IL-4 or IL-13, IL-4Ra
+ macrophages
adopt an alternative phenotype; such macrophages are
termed alternatively-activated macrophages (AAM)
[17-28]. These cells do not express potent pro-inflamma-
tory mediators like the LPS/IFNg treated classically acti-
vated macrophages (CAM). Rather, AAM express a
different set of genes including arg 1 (arginase I), Retnla
(Relma/FIZZ1), and the chitinase family members Chi3L3/
4 (YM1/2), Chi3L1 (brp39) and produce the chemokines
CCL2, CCL11, and CCL24 [20-29]. Furthermore, these
AAM can fuse to form multinucleated giant cells (MNG)
that act to sequester and degrade foreign materials [30,31].
These cells are found during TH2 responses in vivo, and
are thought to be important for immune responses to hel-
minthic parasites and for tissue repair [24-28,32].
Several in vivo studies established a correlation between
t h ep r e s e n c eo fA A Ma n di n f lammation. Mice infected
with Schistosoma mansoni developed granulomatous liver
pathology that correlated with high arginase activity [33].
Furthermore, Heligmosomoides polygyrus infection of mice
elicited a TH2 response and AAM accumulated at the site
of inflammation [32]. The presence of AAM also corre-
lated with recruitment of eosinophils to the lung and peri-
toneal cavity in mice infected with Nippostrongylus
brasiliensis (Nb) or with Sendai virus [34,35]. A reduction
in macrophage numbers resulted in reduced eosinophilia
in both models. Several strategies to delete the IL-4Ra
simultaneously on monocytic and granulocytic cells also
suggested a role for AAM in mediating eosinophilic
inflammation in parasite infection models [36]. A study
characterizing the amplification of AAM formation by IL-
33 also established a correlation between AAM and eosi-
nophilia in a mouse model of allergic lung inflammation
[37]. In addition, increases in AAM in the lungs of female
mice have been linked to the increased susceptibility of
female mice to asthma as compared to male mice [38,39].
Furthermore, studies in children undergoing severe
asthma exacerbations demonstrated an increase in AAM
in the lung [40-42].
These previous studies demonstrated a correlation
between the severity of TH2-driven inflammation and the
presence of IL-4Ra
+ macrophages and AAM [16,32-42].
However, they did not determine whether AAM were suf-
ficient to amplify the inflammatory response. Since human
asthmatics have elevated numbers of AAM and have
increased levels of chitinase proteins in their blood and
lung lavage fluid [43-49], we hypothesized that AAM
directly contribute to the severity of lung pathology. To
directly test this hypothesis, we prepared MCSF-depen-
dent macrophages from the bone-marrow (BMM) of
IL-4Ra
+/+ or IL-4Ra
-/- mice and transferred them to IL-
4RaxRAG2
-/- recipient mice. TH2 cells were provided
exogenously. Strikingly, the adoptive transfer of IL-4Ra
+/+
BMM was sufficient to enhance TH2-driven allergen-
induced lung inflammation. These macrophages were
detected in the lung tissue and were YM1/2- and Mac3-
positive indicating the macrophages were differentiating to
AAM in the TH2 environment. These results demonstrate
that IL-4/IL-13 responsive macrophages positively contri-
bute to the TH2-driven allergic inflammatory response in
the lung and may serve as targets to reduce allergen-
induced exacerbations.
Methods
Reagents
Recombinant murine IL-4 (mIL-4), recombinant human
IL-2 (hIL-2), recombinant human IFNg (hIFNg), and
macrophage colony stimulating factor (MCSF) were
o b t a i n e df r o mR&DS y s t e m s( M i n n e a p o l i s ,M N ) .R a t
anti-mouse IL-4Ra (CD124) M1 antibody was obtained
from BD Pharmingen (Franklin Lakes, NJ). Grade V
Chicken Egg Albumin (OVA) was obtained from Sigma-
Aldrich (St. Louis, MO). Low-Tox
®-M Rabbit Complement
was obtained from Cedarlane Laboratories (Burlington,
NC). Rat anti-mouse IL-12 (p40/p70) and rat anti-mouse
IFNg were purchased from BD Pharmingen (Franklin
Lakes, NJ).
Preparation of macrophages
BALB/c, BALB/c RAG2
-/-,a n dB A L B / cD O 1 1 . 1 0×
RAG2
-/- were purchased from Taconic Farms (Hudson,
NY). BALB/c IL-4Ra
-/- and BALB/c IL-4RaxRAG2
-/-
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sity of Maryland, Baltimore (UMB) [50]. All experimental
procedures were performed under the auspices of our
approved animal protocol in accordance to the guidelines
issued by the Institutional Animal Care and Use Com-
mittee at the University of Maryland, Baltimore.
Bone marrow was isolated from the hind limbs of mice
and cultured overnight in RPMI-1640 supplemented with
10% FBS, 100 units/mL penicillin, 100 μg/mL streptomy-
cin, 2 mM glutamine. Non-adherent cells were collected
by centrifugation and cultured at 1.0 × 10
6 cells/mL in the
presence of 20 ng/ml MCSF to generate bone-marrow
derived, MCSF-dependent macrophages (BMM). After
3 days in culture, fresh media was added. After 6 days in
culture, the adherent cells were isolated using a cell scra-
per and collected by centrifugation. These cells were routi-
nely > 95% F4/80
+/CD11b
+ macrophages. BMM were
washed and transferred to BALB/c IL-4RaxRAG2
-/- mice
by intraperitoneal (IP) injection at 5 × 10
6 cells per mouse.
BMM were cultured in complete RPMI at 1 × 10
6 cells
per ml for 48 h in the presence or absence of IL-4 (10 ng/
ml). The cells were harvested using a non-enzymatic che-
lator (Cellgro, Mediatech, Inc. Manassas, VA) and ana-
lyzed by FACS.
Western blot
Spleens were harvested from recipient mice six weeks after
BMM transfer or from control BALB/c mice (n = 4). Sin-
gle cell suspensions were prepared and pooled. The cells
were then cultured in the presence or absence of IL-4
(10 ng/ml) for 30 min. Cells were lysed and immunopreci-
pitated with rabbit anti-mouse STAT6 (M-20, Santa
Cruz). The precipitates were washed in lysis buffer and
solubilized in SDS sample buffer. The samples were sepa-
rated on 7.5% SDS-polyacrylamide gels before transfer to a
polyvinylidene difluoride (PVDF) membrane. The mem-
branes were then probed with a monoclonal anti-phos-
photyrosine antibody, RC20. The bound antibodies were
detected using enhanced chemiluminescence (Amersham,
Arlington, IL). The blots were stripped and re-probed with
anti-STAT6.
Preparation of TH2 cells
TH2-effectors were prepared in vitro as described
[16,50]. Briefly, lymph nodes were isolated from BALB/c
DO11.10 × RAG2
-/- mice and crushed into a single cell
suspension. Spleens were isolated from BALB/c mice,
crushed into a single cell suspension, and depleted of T-
cells using anti-Thy 1.2 antibody (HO1349 supernatant)
followed Low-Tox
®-M Rabbit Complement. The T-
depleted spleen cells were irradiated at 3000 RADs, and
used as antigen presenting cells.
The lymph node cells (5.0 × 10
5)w e r ec u l t u r e dw i t h
irradiated splenocytes at a 20-fold excess in the presence
of 10 μg/mL anti-IL-12, 10 μg/mL anti-IFNg,5 0n g / m L
mIL-4, and 1 μM OVA peptide. The cells were stimu-
lated for four days and passed at a 1:5 dilution in the
presence of 20 U/mL hIL-2. After 4 days of rest, the
lymph node cells were restimulated as described above
with a 10 fold excess of splenocytes, followed by another
4 days of rest prior to intravenous (IV) transfer to reci-
pient mice. These cells were routinely > 10% + for IL-4
production after restimulation [16].
Asthma induction
TH2 cells were transferred to BALB/c IL-4RaxRAG2
-/-
mice intravenously at 1.0 × 10
7 cells per mouse one day
after the macrophage transfer. The subsequent day
chicken egg ovalbumin (OVA) was adsorbed to aluminum
hydroxide (Alum) at a 1:1 ratio by slow rotation for 30
min at room temperature and injected interperitoneally
into the BALB/c IL-4RaxRAG2
-/- mice delivering 100 μg
of OVA/Alum per mouse. The mice were boosted inter-
peritoneally with 100 μg of OVA/Alum per mouse, pre-
pared as previously described, 14 days after the initial
priming [16]. The mice were exposed, to a 1.0% (w/v)
OVA/PBS solution by nebulization for 20 min on days 19,
22, and 27.
Evaluation of airway inflammation
Mice were anaesthetized 48 h after the last OVA chal-
lenge. Bronchial lavage was performed on each mouse
by inserting a 1 mm tube into the trachea and flushing
the lungs with 1 ml of PBS. The samples were centri-
fuged and the supernatant was used for cytokine analy-
sis. The cellular component of the bronchoalveolar
lavage (BAL) was resuspended in PBS. Total cell counts
were determined. Cytospin preparations of the cells
were stained with Diff-Quick (Dade Behring, Newark,
DE) and differential cell counts were performed based
on cell morphology and staining using light microscopic
analysis.
Lung histology, immunohistochemistry, and
immunofluorescence
The lungs were prepared for histology by perfusing the
right ventricle with PBS. The samples were fixed in 10%
formalin for 2 h at room temperature and then stored in
70% ethanol. Paraffin sections of the samples were pro-
duced and stained with either hematoxylin and eosin
(H&E) or periodic acid Schiff (PAS). The degree of lung
inflammation was scored as previously described [16] ran-
ging from 0 (no inflammation) to 3 (maximum pathology).
Immunohistochemistry was performed as described [51]
using rabbit anti-mouse YM1/2 polyclonal antibody
(StemCell Technologies, Vancouver, BC), rabbit anti-
mouse F4/80, rabbit anti-mouse Mac-3 (BD Pharmingen),
hamster anti-mouse CD3ε monoclonal antibody-PE (BD
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gies, Vancouver, BC).
Lung sections were also analyzed by immunofluores-
cence microscopy. The sections were de-paraffinized
and treated with an antigen retrieval solution of 0.1 M
citric acid, 0.1 M sodium citrate for 20 min. After
changes in PBS, the slides were immersed in methanol/
0.3% H2O2 for 30 min to exhaust endogeneous peroxi-
dase activity. The sections were then preincubated with
10% Goat Serum for 20 min at room temperature, fol-
lowed by Rat anti-Mouse Mac-3 (BD Pharmingen) or
non-immune rat serum for 1 h at room temperature.
After PBS washes, the secondary antibody Goat anti-Rat
Alexa Fluor 555 (Molecular Probes by Life technologies)
was applied for 30 min at room temperature. The slides
were rinsed in PBS and incubated with rabbit anti-
mouse YM1/2 (StemCell Technologies Inc.) or non-
immune rabbit serum for 1 h at room temperature, fol-
lowed by goat anti-Rabbit Alexa Fuor 488 (Invitrogen)
for 30 min. The slides were rinsed in PBS and incubated
with DAPI for 2 min. Fluorescently stained slides were
viewed on a Nikon E-800 fluorescent microscope using
a Nikon 40×/0.75 Plan Fluor objective. Blue (DAPI), red
(Mac3), and green (YM1/2) images of the same field
were captured by a Retiga EXi camera (Q imaging,
Canada) operated by Volocity software (PerkinElmer
Inc.) using identical capture settings for experimental
and control slides. The 3 color images were merged.
Five fields were analyzed for the total number of nuclei,
total number of cells staining red only, number of cells
staining green only, and number of cells with both col-
ors (yellow). The percentage of cells in each category
was calculated by dividing each number by the total
number of nuclei per field.
FACS analysis
To prepare single cell suspensions from whole lungs, tis-
sues were subjected to DNAse (Roche) and collagenase
(Worthington Biochemical) treatment for 30 min at 37°C
as described previously [52]. Tissue digests then were
passed through 40 μm cell strainers (BD Falcon). Cells
were collected by centrifugation and washed three times
in a PBS/2% FBS solution (FACS buffer). The cells were
resuspended in FACS buffer and pushed through a filter
cap. Fc receptors were blocked using a rat anti-mouse
CD16/CD32 antibody (2.4 G2, BD Pharmingen, Franklin
Lakes, NJ). Cells were then incubated for 30 min at 4°C
in the presence of anti-F4/80, anti-CD11b, and anti-IL-
4Ra. Cells were collected by centrifugation, washed three
times and resuspended in FACS buffer. Flow cytometric
analysis was performed using Becton Dickinson FACS-
can™ and Becton Dickinson FACSCalibur™ machines.
Live cells were gated on forward by side scatter and ana-
lyzed for F4/80 by CD11b staining. The cells expressing
high levels of both CD11b and F4/80 have been shown to
be macrophages [52,53] and these cells were analyzed for
expression of IL-4Ra. Data was analyzed using FlowJo
software v8.5.3 (Treestar, CostaMesa, CA).
Single cell suspensions of BMM were incubated with Fc
Block (2.4 G2, BD Biosciences) followed by staining with
anti-Mac3-PE or isotype control. Cells left unstained or
treated with isotype control antibodies were used as
controls.
Antibodies used for flow cytometric analysis include:
murine IL-4Ra-M1 (R-Phycoerythrin (PE) or FITC-conju-
gated rat anti-mouse CD124) (BD Pharmingen, Franklin
Lakes, NJ), F4/80 (eBiosciences), rat anti-mouse CD11b
(Integrin am chain, Mac-1 a chain) monoclonal antibody-
PE (BD Pharmingen), rat anti-mouse Mac-3-PE (BD), and
rabbit anti-YM1 (StemCell Technologies, Inc).
Results
YM1
+ AAM are present in lungs of Chimeric mice
receiving IL-4Ra
+ bone-marrow and TH2 cells
Using bone-marrow chimeras, we previously demon-
strated a strong correlation between the severity of allergic
lung inflammation induced by the classic alum/ovalbumin
prime/boost/challenge protocol and the presence of IL-
4Ra
+ bone-marrow [16]. The enhanced inflammation was
most evident when IL-4Ra
+/+ bone-marrow was trans-
ferred to IL-4Ra
-/- recipient mice in the presence of TH2
cells. Since bone-marrow derived macrophages adopt an
alternative phenotype in response to the TH2 cytokines
IL-4 and IL-13 [20], we analyzed lung sections from the
OVA-primed chimeric mice for the expression of macro-
phage markers (Figure 1). We found that lung sections
from IL-4RaxRag2
-/- mice receiving IL-4Ra
+/+ bone-mar-
row (BM) had greater inflammation and enhanced staining
for F4/80 than lungs from mice receiving IL-4Ra
-/- BM.
Furthermore, the lungs of OVA-primed mice receiving IL-
4Ra
+/+ BM showed strong staining for the AAM marker
YM1/2 while lungs from mice receiving IL-4Ra
-/- BM
were negative for YM1/2. These results show that expres-
sion of IL-4Ra on bone-marrow derived cells is required
for AAM formation during allergic lung inflammation in
vivo.
Transfer of IL-4Ra
+ BMM was sufficient to enhance TH2-
driven allergic lung inflammation
Human asthmatics have elevated numbers of macro-
phages in their lungs and increased amounts of chitinase
family members in their blood and lung lavage fluid
[41-49]. An increase in AAM was observed in children
undergoing severe asthma exacerbation [40]. Further-
more, the presence of AAM has been correlated with
eosinophilic inflammation induced by infection and by
allergen challenge [32-39]. Therefore, we hypothesized
that the IL-4Ra
+ macrophages, capable of becoming
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F4/80
YM1/2
Rab IgG
BM:                   IL-4RD-/-                IL-4RD+/+
Figure 1 AAM are present in the lungs of chimeric mice receiving IL-4Ra
+/+ bone-marrow. Balb/c IL-4RaxRAG2
-/- mice were irradiated and
reconstituted with bone-marrow cells isolated from IL-4Ra
-/- or IL-4Ra
+/+ mice as previously described [16]. Six weeks later, the mice were
provided with OVA specific TH2 effectors (1 × 10
7/mouse) by tail vein injection. They were then sensitized to 100 μg chicken egg ovalbumin
(OVA) adsorbed to aluminum hydroxide (Alum) via i.p. injection on day 0 and boosted with the same reagent on day 14. Mice were exposed to
1% OVA in PBS by nebulization for 20 min each day on days 19, 22, and 27. Lung sections from OVA/alum primed mice were prepared and
stained with H&E, anti-F4/80, anti-YM1/2, or control rabbit IgG as indicated. Digital images from a representative mouse (n = 4) for the 2 groups
are shown (20X). These results are representative of 3 independent experiments.
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allergic inflammation rather than simply acting as bystan-
ders. To test the direct contribution of IL-4Ra+m a c r o -
phages on the severity of allergic lung inflammation, we
developed a macrophage transfer approach (Figure 2).
We chose this transfer approach as opposed to a macro-
phage depletion approach because most depletion strate-
gies are not completely specific for macrophages and
they cannot maintain the depleted state over the length
of the asthma protocol [34,36,54].
We utilized bone-marrow-derived, M-CSF dependent
macrophages (BMM) for transfer. We found that BMM
prepared from either RAG2
-/- or IL-4RaxRAG2
-/- mice
were routinely > 95% CD11b
+ (Figure 3A); as expected
BMM isolated from RAG2
-/- mice expressed the IL-4Ra
while those isolated from IL-4RaxRAG2
-/- mice did not
(Figure 3B). IL-4Ra
+ BMM respond to IL-4 or IL-13 by
inducing classic AAM genes while IL-4Ra
-/- BMM do
not [20,55]. To determine whether transfer of BMM was
feasible, we performed preliminary transfer studies. We
found that IL-4Ra
+/+ BMM transferred into IL-4Ra
-/-
mice by IP injection could be detected in the spleen up
to 6 weeks after transfer (Figure 3C). Furthermore, sple-
nocytes from mice receiving IL-4Ra
+/+ BMM, but not
IL-4Ra
-/-BMM, demonstrated the tyrosine phosphoryla-
tion of STAT6 in response to in vitro IL-4 treatment,
albeit at reduced levels when compared to control
BALB/c splenocytes (Figure 3D). These results demon-
strate that macrophages adoptively transferred intraperi-
toneally are capable of populating lymphoid tissue.
To examine the impact of these BMM on allergic
inflammation in vivo, we transferred BMM prepared from
IL-4Ra positive or negative mice to IL-4RaxRAG2
-/-
recipient mice and provided in vitro primed wild type
TH2 effectors one day later by IV injection (Figure 2).
These recipient mice were then immunized intraperitone-
ally with alum alone or OVA/alum and challenged with
OVA as shown (Figure 2). The adoptive transfer of IL-4Ra
+/+ BMM resulted in severe TH2-driven, OVA-induced
allergic lung inflammation in IL-4RaxRAG2
-/- recipient
mice as shown in representative H&E images (Figure 4A,
panels e, f), while transfer of IL-4Ra
-/- BMM resulted in
lower levels of lung inflammation (Figure 4A, panels b, c).
Little to no inflammation was observed in the absence of
TH2-effectors, as expected (Figure 4A, panels a and d; Fig-
ure 4B). The transfer of IL-4Ra
+/+ BMM greatly enhanced
the amount of TH2-driven, OVA-induced inflammation
around airways and blood vessels in the lungs (pathology
score: 3+) as compared to transfer of IL-4Ra
-/- BMM
(pathology score: 1+) (Figure 4B). Numerous airways were
filled with eosinophils and mononuclear cells in the lungs
of mice receiving IL-4Ra
+/+ BMM (Figure 4A, panel f).
Since in both cases the recipient mice lacked IL-4Ra,t h e
lung epithelial cells were negative for PAS staining, indi-
cating they were not producing mucus (data not shown)
[56,57].
The cellular composition in the bronchoalveolar lavage
(BAL) of individual mice was evaluated by differential
staining after cytospin. Representative images are shown
in Additional file 1: Figure S1. Mice that received TH2
cells alone or TH2 cells plus IL-4Ra
-/- BMM showed a
similar pattern in BAL cell numbers after priming and
challenge with OVA (Figure 4C). For example, in the
absence of tranferred macrophages there were 6.1 × 10
5
macrophages and 2.5 × 10
5 eosinophils recovered in the
BAL while in the presence of IL-4Ra
-/- BMM this was
Culture BM in MCSF 
for 7 days. 
Day 14:  Boost mice IP 
Alum or 100 P Pg Ova/Alum
Day 29: Isolate BAL, 
Lungs 
Day 19, 22, and 27: Nebulize 
all mice with 1% Ova in PBS 
Day 0:  Immunize with 
Alum or 100 Pg Ova/Alum
Day -2: Transfer BMM 
to Recipient IP 
Day -1: Inject DO11.10 
TH2 cells IV
Figure 2 Protocol for macrophage transfer and inflammation induction. Bone-marrow derived macrophages (BMM) were derived from IL-
4Ra
+/+ or IL-4Ra
-/- mice on the RAG2
-/- background as described in the Materials and Methods. BMM were washed and transferred to BALB/c
IL-4RaxRAG2
-/- mice by IP injection at 5 × 10
6 cells per mouse. The next day, in vitro differentiated OVA-specific TH2 cells were injected IV at 1 ×
10
7 per mouse. They were then sensitized to 100 μg chicken egg ovalbumin (OVA) adsorbed to aluminum hydroxide (Alum) via i.p. injection on
day 0 and boosted with the same reagent on day 14. Mice were exposed to 1% OVA in PBS by nebulization for 20 min each day on days 19,
22, and 27.
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5 macrophages and 3.6 ×
10
5 eosinophils. The total cell number recovered in the
BAL was increased ~1.5 fold in the presence of IL-4Ra
-/-
BMM. However, mice that received TH2 cells plus IL-
4Ra
+/+ BMM showed an altered BAL cell composition.
In the presence of IL-4Ra
+/+ BMM there was an increase
in total BAL cells as compared to the other 2 groups and
this increase was largely due to a significant increase in
eosinophils. On average there were 10.4 × 10
5 macro-
phages, similar to the IL-4Ra
-/- BMM group, and 9.8 ×
10
5 eosinophils representing a greater that 2-fold increase
in the number of eosinophils.
A similar trend was apparent when the percentage of
eosinophils in the BAL was evaluated (Figure 4D).
Transfer of TH2 effectors alone resulted in some airway
eosinophilia (10% eosinophils in the BAL) in response
to inhaled OVA (Figure 4D). This level of eosinophilia
was enhanced by immunization with OVA to 30%. The
addition of IL-4Ra
-/- BMM did not alter the level of
TH2-driven eosinophilia. However, transfer of IL-4Ra
+/+
B M Mr e s u l t e di na ni n c r e a s ei na i r w a ye o s i n o p h i l i ai n
response to inhaled OVA (20%); this was further
increased by OVA immunization to 55%. Thus, transfer
of IL-4Ra
+/+ macrophages significantly enhanced TH2-
dependent, OVA-stimulated airway eosinophilia.
IL-4Ra
+ BMM adopt the alternative phenotype in vivo
Lung digests were prepared from OVA immunized and
challenged mice to analyze the recruitment of the trans-
ferred BMM to the lungs (Figure 5). Mice receiving either
IL-4Ra
-/- or IL-4Ra
+/+ B M Ms h o w e da ni n c r e a s ei nt h e
total numbers of lung cells recovered as compared to
A.                                                                   B.                                      
C.                                                                   D.
anti-CD11b
RAG2-/-                         IL-4RxRAG2-/-
96% 97%
BMM
anti-IL-4RD
pre-transfer
RAG2-/-                                           
IL-4RxRAG2-/-
CD11b+ SPLEEN
post-transfer
anti-IL-4RD
RAG2-/-                                           
IL-4RxRAG2-/-
anti-PY
anti-STAT6
IL-4 :     -      +      -      +     -      +
IL-4RD+/+   IL-4RD-/-        -
BMM         BMM
IL-4RxRAG2-/- BALB/c
Figure 3 Phenotype of macrophages pre- and post- transfer.A .B M Mw e r ep r e p a r e df r o mR A G 2
-/- and IL-4RaxRAG2
-/- mice and were
stained with anti-CD11b (solid line) or control antibody (dotted line) as indicated and analyzed by FACS. B. BMM were prepared from RAG2
-/-
(solid line) and IL-4RaxRAG2
-/- (dotted line) mice and were stained with anti-IL-4Ra as indicated and analyzed by FACS. C. BMM were prepared
from RAG2
-/- (solid line) and IL-4RaxRAG2
-/- (dotted line) mice and transferred to BALB/c IL-4RaxRAG2
-/- mice by IP injection at 5 × 10
6 cells per
mouse. Six weeks later spleens were harvested and stained with anti-CD11b and anti-IL-4Ra and analyzed by FACS. Live spleen cells were gated
on expression of CD11b; the IL-4Ra staining histograms are shown. These results are representative of 3 independent experiments. D. BMM were
prepared from RAG2
-/- (IL-4Ra
+/+) and IL-4RaxRAG2
-/- (IL-4Ra
-/-) mice and transferred to IL-4RaxRAG2
-/- mice by IP injection at 5 x10
6 cells per
mouse. Six weeks later spleens were harvested and single cell suspensions were prepared. In addition, single cell suspensions were prepared
from untreated BALB/c mice. Pooled spleen cells were cultured in the presence or absence of IL-4 (10 ng/ml) for 30 min as indicated. Cell
lysates were prepared and immunoprecipitated with anti-STAT6. The precipitates were analyzed by western blotting with anti-phosphotyrosine
antibody. The membranes were stripped and re-probed with anti-STAT6.
Ford et al. BMC Immunology 2012, 13:6
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Figure 4 Transfer of IL-4Ra
+/+ BMM enhances the TH2-driven, OVA-induced eosinophilic inflammation in the lungs and airways of
mice. BMM were prepared from IL-4Ra
+/+ or IL-4Ra
-/- mice as described above. BMM (5 × 10
6) were transfered by IP injection to IL-4RaxRAG2
-/-
mice on day -1. On day 0 mice were injected with PBS alone or with TH2 cells derived from D011.10 mice as indicated (1 × 10
7). The mice were
immunized with OVA/alum on day 1 as indicated, followed by boost and challenge as described in Figure 2. Lung sections from OVA/alum
primed mice were prepared and stained with H&E. A. Several digital images (A-F) from a representative mouse from each group (n = 4) are
shown at 10 and 20X. B. The slides from individual mice were evaluated for the degree of pathology (0-3) as described in Materials and
Methods. The mean score for each group is represented in the form of bar graphs ± SEM. In most cases the SEM was too small to show on the
graph. Significant differences between the two groups noted were determined using the Student’s T-test. ** (p < 0.01) C. BMM were prepared as
described above and transfered by IP injection to IL-4RaxRAG2
-/- mice on day -1. On day 0 all mice were injected with TH2 cells derived from
D011.10 mice (1 × 10
7). The mice were immunized with alum or OVA/alum on day 1 as indicated, followed by boost and challenge as described
in Figure 2. The BAL from individual mice (n = 3-4) was evaluated by differential counting after cytospin. Total numbers of cells present in the
BAL are represented in the form of bar graphs ± SEM (T, total cells; M, macrophages; E, eosinophils; L, lymphocytes; and P, polymorphonuclear
leukocytes). ** Significant differences between the two groups noted were determined using the Student’s T-test (p < 0.01). D. The percentage
of eosinophils in the BAL isolated from the individual mice is shown with the mean of the values represented by the bar. Significant differences
between groups were determined using the Student’s T-test. * (p < 0.05) These results are representative of 3 independent experiments.
Ford et al. BMC Immunology 2012, 13:6
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Page 8 of 17mice receiving TH2 cells alone from 5.6 × 10
7 to 14.0 ×
10
7 and 14.2 × 10
7 total cells, respectively. Mice that
received TH2 effectors alone showed few F4/80
+,
CD11b
hi cells (15%, 0.8 × 10
7)i nt h el u n g s( F i g u r e5 A ,
C). Our previous reports showed that F4/80
+,C D 1 1 b
hi
cells in the lungs are macrophages [52,53]. Mice receiving
either IL-4Ra
-/- or IL-4Ra
+/+ BMM showed an increase
in the percentages and the numbers of F4/80
+,C D 1 1 b
hi
cells in the lungs (64%, 9.0 × 10
7 and 62%, 8.8 × 10
7,
respectively). The F4/80
+, CD11b
hi cells were positive for
IL-4Ra expression in the mice that received IL-4Ra
+/+
BMM, but not in the mice that received IL-4Ra
-/- BMM
(Figure 5B), showing that the transferred IL-4Ra
+/+
BMM were able to localize to the lung.
To analyze the presence of AAM in the lung tissue,
lung sections were analyzed by immunohistochemistry
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11% 62%
64% 25%
No BMM                         IL-4RD-/- BMM                        IL-4RD+/+ BMM
BMM F4-80-/Cd11b-     F4-80+/CD11blo       F4-80+/CD11bhi       F4-80-/CD11bhi
None   0.2 x 107         3.4 x 107               0.8 x 107                 1.2 x 107          
IL-4RD-/-       0.4 x 107         3.0 x 107               9.0 x 107                 1.7 x 107          
IL-4RD+/+    0.3 x 107         3.6 x 107               8.8 x 107                 1.6 x 107
C.
Figure 5 Phenotype of macrophages in the lungs of recipient mice. BMM were prepared from IL-4Ra
+/+ or IL-4Ra
-/- mice as described
above. Where indicated BMM (5 × 10
6) were transfered by IP injection to IL-4RaxRAG2
-/- mice on day -1. On day 0 all mice were injected with
TH2 cells derived from D011.10 mice (1 × 10
7). The mice were immunized with OVA/alum on day 1 as indicated, followed by boost and
challenge as described in Figure 2. Lung digests were prepared from mice (n = 4) as described in Materials and Methods, pooled, and counted.
Lung cells were stained with anti-CD11b, and anti-F4/80, along with anti-IL-4Ra or control IgG. A. Live cells were gated on forward by side
scatter and analyzed for F4/80 by CD11b staining. B. The cells were gated for high expression of CD11b and F4/80 and analyzed for expression
of IL-4Ra. The histograms comparing control staining (dotted line) to anti-IL-4Ra staining (solid line) of the gated cells is shown. C. The numbers
of cells expressing the markers were calculated using the percentages of cells in each quadrant in Panel (A) and the total lung cells recovered.
These results are representative of 2 independent experiments.
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Page 9 of 17(Figure 6). The lungs of mice receiving IL-4Ra
+/+ BMM
showed enhanced F4/80 staining of inflammatory cells
surrounding airways and strong staining for YM1/2 in
cells in the lung tissues and in the airways (Figure 6A).
The YM1/2 staining was dependent on the presence of
TH2 cells, since in their absence we did not detect any
YM1/2 positive cells in the lungs of mice receiving IL-4Ra
+/+ BMM (Additional file 2: Figure S2). The lungs of mice
receiving IL-4Ra
-/- BMM were largely negative for YM1/2
even though they showed modest inflammation. None of
these sections were positive for iNOS, a marker of classi-
cally activated macrophages (data not shown). Taken
together, these results show that the IL-4Ra
+/+ BMM
were able to differentiate to the alternative phenotype in a
TH2 environment. The lungs of mice receiving either the
IL-4Ra
-/- or the IL-4Ra
+/+ BMM were equally positive for
CD3 staining, indicating that the T-cells were recruited to
the inflamed lung in both cases (Figure 6A, B).
To characterize the YM1/2
+ cells further, we performed
immunhistochemistry on serial sections of the same lung
region using antibodies against F4/80, Mac3, and YM1/2
(Figure 7A). Previous studies had shown that parasitic
infection with Nb induced the expression of AAM genes
in Mac3
+ macrophages in the lung suggesting that Mac3
(also known as CD107b and lysosomal-associated mem-
brane protein 2, LAMP2) may also be induced by IL-4 and
IL-13 [58]. Indeed, we found that IL-4 treatment of BMM
in vitro increased expression of Mac3 (Additional file 3:
Figure S3). Furthermore, both anti-Mac3 and anti-YM1/2
stained the large mononuclear cells found in close associa-
tion with eosinophils in the airways and scattered in the
lung tissue; several examples are marked by the arrow
heads (Figure 7A). F4/80 also stained these cells, in addi-
tion to other cells marked by the asterisk surrounding the
blood vessels; inflammatory cells surrounding blood ves-
sels were largely negative for Mac3 and YM1/2. These
results suggest that both Mac3 and YM1/2 can mark
AAM in the inflamed lung, while F4/80 stains AAM as
well as other inflammatory cells.
To determine whether macrophages co-expressed
Mac3 and YM1/2, we stained the lung sections for both
and analyzed them by immunofluoresence (Figure 7B).
We found that a substantial fraction (25%) of the
nucleated cells in the airway expressed both Mac3 and
YM1/2. We also found cells expressing either Mac3
(30%) or YM1/2 (34%) alone and cells lacking expres-
sion (11%) suggesting heterogeneity in the macrophage
population. These observations show that Mac3 and
YM1/2 can be co-expressed in the inflamed lung.
The presence of IL-4Ra
+/+ BMM enhanced the levels of
TNFa and Chemokines in the BAL fluid
To determine whether the presence of IL-4Ra
+/+ BMM
altered cytokine or chemokine production, the amount of
cytokines and chemokines in the BAL fluid were analyzed
using Pierce Search Light multiplex analysis (Figure 8).
The concentrations of IL-4 and IL-5 in the BAL fluid
were similar in mice receiving IL-4Ra
-/- or IL-4Ra
+/+
BMM, consistent with the presence of equal numbers of
T-cells in the lung (Figure 6). There was a trend of more
IL-13 in the BAL of mice receiving IL-4Ra
+/+ BMM, but
this was not statistically significant. TNFa levels in the
BAL fluid were greater in mice receiving IL-4Ra
+/+
BMM; the difference was statistically significant (p <
0.0001). Furthermore, the increased levels of eotaxin-1,
RANTES, and MCP-1 in mice receiving IL-4Ra
+/+ BMM
were statistically significant; levels of TARC were similar
between the two groups.
Discussion
The contribution of IL-4, IL-13 and IL-4Ra to allergic
asthma disease progression and pathological characteris-
tics has been examined in some detail [7,8,11,13]. How-
ever, the role of AAM in allergic lung inflammation has
remained unclear. Several studies, including our own, have
demonstrated a correlation between the presence of IL-
4Ra+ macrophages and enhanced eosinophilic inflamma-
tion using infection and allergic models in mouse and
man [16,32-47]. Previous studies have used clodronate
loaded liposomes to deplete macrophages to demonstrate
their role in infection-induced inflammation [35]. While
informative, this approach is limited because clodronate
can deplete any phagocytic cell, not only macrophages; the
liposomes can induce a confounding inflammatory
response on their own; and the depletion only lasts for 3
days [54].
In this study, we tested whether IL-4Ra
+ macrophages
were sufficient to enhance allergen-induced eosinophilic
inflammation. Since we provided OVA-specific, primed
TH2-effectors, additional exposures to OVA would mimic
allergen-induced exacerbation. Using this approach, we
found that adoptive transfer of IL-4Ra
+/+ BMM, but not
IL-4Ra
-/- BMM, significantly enhanced the TH2-depen-
dent, OVA-induced recruitment of eosinophils to the
lung. As would be expected in this model of inflammation,
we found little to no inflammation in the absence of TH2
cells. Thus, in the presence of TH2 cells, transfer of IL-
4Ra
+ macrophages is sufficient to enhance inflammation.
However, it is not entirely clear whether they are the pri-
mary effectors of the enhanced inflammation or whether
they stimulate another cell type.
We found that lungs from OVA-challenged IL-4Ra-
deficient mice that received TH2 cells and IL-4Ra+ BMM
showed positive staining for YM1/2. Immunohistochemis-
try of serial sections and immunofluorescence showed
substantial overlap in staining of macrophages with YM1/
2 and Mac3. The F4/80 staining showed a broader profile,
overlapping with the YM1/2 and Mac3 staining, but also
Ford et al. BMC Immunology 2012, 13:6
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Figure 6 Transfer of IL-4Ra
+/+ BMM leads to the presence of AAM in the lungs of mice. A. Lung sections from the OVA/alum primed mice
shown in Figure 4 were stained with anti-F4/80, anti-YM1/2, or anti-CD3 as indicated. Images from a representative mouse from each group are
shown at 10X or 20X as indicated. CD3+ cells appear brown. B. The CD3+ cells in each 20X field were counted (n = 5). The average number of
CD3+ cells per field were calculated and graphed. Data represented as cell counts ± SEM. These results are representative of 3 independent
experiments.
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Figure 7 YM1/2 and Mac3 staining coincide in the allergic lung. A. Serial sections of lungs from a representative OVA/alum-primed mouse
that received IL-4Ra
+/+ BMM were stained with H&E, anti-F4/80, anti-Mac3, or anti-YM1/2 as shown. Digital images were taken from the same
region of the lung at 40X and 100X. Arrow heads highlight the staining of representative macrophages in the airways, while the asterisk
highlights staining of macrophages surrounding blood vessels. B. Co-expression by immunofluorescence microscopy. A representative lung
section was stained with rat anti-Mac3 and rabbit anti-YM1/2 (or control serum), followed by goat anti-Rat-PE and goat anti-rabbit-FITC. Nuclei
were stained with DAPI. Digital images were captured for each color and processed as described in Materials and Methods. The 3 color images
were merged into a single image. Appearance of yellow indicates expression of both Mac3 and YM1/2. C. Five fields were analyzed for the total
number of nuclei, total number of cells staining red only, number of cells staining green only, and number of cells with both colors (yellow). The
percentage of cells in each category was calculated by dividing each number by the total number of nuclei per field. These results are
representative of 2 independent experiments.
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Page 12 of 17staining other inflammatory cells, especially cells cuffing
blood vessels. Our results are consistent with those from
the Nb infection model showing that Mac3+ cells express
AAM markers [58]. However, whether Mac3 will be a reli-
able cell surface marker for AAM in inflamed tissues
remains to be firmly established. Using immunofluores-
cence microscopy, we observed an interesting heterogene-
ity in expression of Mac3 and YM1/2 with Mac3
-/YM1/2
-,
Mac3
+/YM1/2
-,M a c 3
-,Y M 1 / 2
+, and Mac3
+,Y M 1 / 2
+ cells
present in the inflamed lungs. Whether these different
subsets mediate different effector functions is unknown.
AAM have been shown to participate in other TH2
mediated inflammatory responses. Mice infected with
nematode parasites induced the localized development of
AAM in response to IL-4 [32]. Recruitment of eosinophils
to the lung and peritoneal cavity in mice infected with Nb
was dependent on macrophages; the absence of macro-
phages greatly prevented eosinophil recruitment [34].
Furthermore, intratracheal administration of in vitro dif-
ferentiated AAM elevated the typically low level of allergic
inflammation seen in male mice [39]. Taken together, our
results and those from the other parasite infection models
and allergic lung inflammation models strongly suggest
that AAM are important, active contributors to inflamma-
tion and are not just bystander cells responding to the
TH2 cytokines.
In our BMM transfer model, all host cells were IL-
4Ra
-/-, including resident lung macrophages, and thus
were unable to respond to IL-4 or IL-13. We detected
IL-4Ra+ macrophages in the lungs of mice that received
IL-4Ra
+/+ BMM by intraperitoneal injection. In addi-
tion, we detected YM1/2+ macrophages in the lungs of
these mice, but not in lungs of mice that received BMM
lacking the IL-4Ra. These results show that the trans-
ferred BMM likely respond to the IL-4/IL-13 produced
by the TH2 effectors in vivo and can localize to the
lung. This is in contrast to studies using a parasite infec-
tion model reported by Jenkins et al. [59] where the
majority of lung AAM was derived from proliferating
resident lung cells and not from new immigrants. It is
possible resident tissue macrophages proliferated in our
model, however, since they lacked IL-4Ra,t h e yw o u l d
not be able to differentiate into AAM. The relative con-
tribution of AAM derived from newly arrived inflamma-
tory macrophages versus AAM derived from resident
lung macrophages to eosinophilic inflammation remains
to be established.
An important question arising from these studies is
how the IL-4Ra
+ macrophages actively enhance the
inflammatory response. IL-4/IL-13 stimulated macro-
phages make a number of factors including high levels of
arginase 1, and chitinase and chitinase-like family mem-
bers, however their contribution to allergic inflammation
is not well understood [17-20]. Deletion of arginase 1
had no effect on the level of allergic inflammation [60].
Deletion of the chitinase family member brp39 pro-
foundly suppressed allergic inflammation by an unknown
mechanism [61]. Another chitinase like family member,
YM1/2 has been shown to enhance TH2 cytokine pro-
duction by T-cells [62].
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Figure 8 Transfer of IL-4Ra
+ BMM alters cytokine and chemokine levels in the bronchalveolar lavage fluid (BAL). BMM were prepared
from IL-4Ra
+/+ or IL-4Ra
-/- mice as described above. BMM (5 × 10
6) were transfered by IP injection to IL-4RaxRAG2
-/- mice on day -1. On day 0
all mice were injected with TH2 cells derived from D011.10 mice (1 × 10
7). The mice were immunized with OVA/alum on day 1 as indicated,
followed by boost and challenge as described in Figure 2. The BAL fluid from individual mice (n = 3-4) was evaluated for cytokine and
chemokine levels using Pierce Searchlight. The mean +/- SEM is shown. These results are representative of 3 independent experiments.
Significant differences between groups was determined using the Student’s T-test.
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Page 13 of 17IL-4/IL-13 stimulation of macrophages induces the pro-
duction of eotaxin 1 and 2 (CCL11 and CCL24) that are
important for the chemotaxis of eosinophils [29]. This
chemokine production is amplified by IL-33 leading to
enhanced eosinophilic inflammation [37]. AAM also pro-
duce MDC (macrophage-derived chemokine; CCL22) and
TARC (thymus and activation-regulated chemokine;
CCL17) that recruit macrophages and TH2 cells respec-
tively [20]. IL-4 stimulation of AAM has been shown to
enhance the production of MIP-1a (macrophage inflam-
matory protein-1; CCL3) a granulocyte chemokine [29].
The ability of AAM to produce chemokines may explain
the enhanced recruitment of eosinophils we observed in
mice receiving IL-4Ra
+/+ macrophages. We observed
increased amounts of eotaxin-1, RANTES, and MCP-1 in
the BAL fluid of mice receiving IL-4Ra
+/+ BMM, although
the precise cellular source of these chemokines is not
known. They could be derived from the AAM present in
the lung and the BAL or they could be derived from
another cell type responding to products made by the
AAM.
In this regard, Medoff et al. found that an F4/80
- mye-
loid cell type was able to produce chemokines in a
STAT6-dependent manner that enhanced both T-cell and
eosinophil recruitment to the lung [63]. Since AAM have
been shown to produce IL-13, it is possible the AAM are
i n d i r e c t l yr e s p o n s i b l ef o rt h ei n c r e a s ei nc h e m o k i n e s
found in the BAL by producing IL-13 that can act on
other myeloid cell populations in the lung [35]. Another
group has shown that AAM regulate the activity of mye-
loid dendritic cells in female mice, suggesting a mechan-
ism whereby females are more susceptible to lung
inflammation than males [39]. While not a focus of this
study, it is possible products made by AAM enhance the
antigen presenting function of dendritic cells leading to
enhanced T-cell activation. Clarification of the specific
myeloid/macrophage population directly responsible for
the enhanced eosinophilic inflammation observed after IL-
4Ra
+ BMM transfer will require further investigation.
AAM may provide an environment hospitable to TH2
cells establishing a reciprocal relationship between these
two cell types during the course of allergic inflammation.
Such a relationship has been described as the innate-adap-
tive axis in asthma [35,41]. Chemokines produced by
AAM such as TARC (CCL17) may enhance the recruit-
ment of TH2 cells to the site of inflammation. Addition-
ally, AAM increase expression of the IL-1 receptor
antagonist (IL-1Ra), a decoy for IL-1 [17-20]. AAM can
also produce IL-10 [17]. IL-10 suppresses IFNg and
STAT1 regulated responses. Since IFNg can suppress TH2
differentiation, the IL-10 may act to perpetuate the Type 2
inflammatory response. Production of IL-1Ra and IL-13
by AAM may suppress the differentiation and function of
TH17 cells [64]. In our model, where we provide high
numbers of in vitro differentiated TH2 cells exogenously,
these regulatory processes may not be apparent. We did
not see a difference in the number of T-cells in the lungs
or a difference in the amount of IL-4 or IL-5 in the BAL
fluid between the IL-4Ra+ or IL-4Ra- transfer groups sug-
gesting that the TH2 cells were being recruited and acti-
vated sufficiently in both settings. Additionally, there was
no difference in the amount of IFNg in the BAL fluid,
while the levels of IL-17 were below detection in all groups
(data not shown).
However, we did observe a significant increase in the
levels of TNFa in the BAL of mice receiving IL-4Ra +
BMM. While high levels of TNFa are typically associated
with TH1-and TH17-mediated inflammatory diseases,
TNFa levels have also been correlated with allergic inflam-
mation in mice and with asthma severity in humans
(reviewed in [65]. TNFa could play a role in the pathogen-
esis of asthma by stimulating a number of responses in
inflammatory cells and structural cells including the
recruitment and activation of eosinophils, the activation of
mast cells, and the upregulation of adhesion molecules on
endothelial and epithelial cells. The cellular source of our
observed increase in TNFa in the BAL is unknown. Simi-
lar to the chemokines, many cell types are capable of pro-
ducing TNFa including T-cells, macrophages, eosinophils,
and epithelial cells [65]. AAM have also been shown to
produce TNFa which can be enhanced by bacterial infec-
tion or LPS treatment [66,67]. Thus, it is possible the full
set of cytokines and chemokines produced by AAM could
favor TH2 dominance and promote a robust inflammatory
environment in the lung.
Conclusions
In summary, we have shown that transfer of IL-4Ra+
macrophages, but not IL-4Ra- macrophages, is sufficient
to enhance TH2-driven allergic inflammation. Since AAM
were only present in the lungs of mice receiving IL-4Ra+
BMM, these findings suggest that AAM contribute to the
severity of allergic lung inflammation in the ovalbumin
model. This contribution could be mediated by products
made by AAM including chemokines and chitinase family
members. An innate:adaptive axis has recently been appre-
ciated in mice and humans, especially during acute asthma
exacerbations [35,41]. It will be informative to delineate
the most important mediators produced by AAM that
lead to enhanced inflammation in mouse models and in
humans.
Additional material
Additional file 1: Figure S1 Differential staining of cells in the BAL.
BMM were prepared from BALB/c RAG2
-/- (IL-4Ra
+/+)o rI L - 4 R axRAG2
-/- (IL-
4Ra
-/-) mice by culturing in MCSF for 7 days. These BMM (5 × 10
6)w e r e
transfered by IP injection to IL-4RaxRAG2
-/- mice on day -1. On day 0 all
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Page 14 of 17mice were injected with TH2 cells derived from D011.10 mice (1 × 10
7). The
mice were immunized with OVA/alum on day 1 as indicated, followed by
boost and challenge as described in Figure 2. The cytospins of cells in the
BAL were stained with Diff-Quick. Representative high power fields (100X)
are shown.
Additional file 2: Figure S2 TH2-dependence of AAM differentiation
in vivo. BMM were prepared from IL-4Ra
+/+ mice and transferred (5 ×
10
6) by IP injection to IL-4RaxRAG2
-/- mice on day -1. On day 0 mice
were injected with PBS alone or with TH2 cells derived from D011.10
mice as indicated (1 × 10
7). The mice were immunized with OVA/alum
on day 1 as indicated, followed by boost and challenge as described in
Figure 2. Lung sections from OVA/alum primed mice were prepared and
stained with anti-YM1/2. Images from a representative mouse from each
group are shown at 40X or 100X as indicated (Arrows show YM1/2+ cells
in the 100X image).
Additional file 3: Figure S3 Increased expression of Mac3 in IL-4-
treated macrophages. BMM were prepared from IL-4Ra
+/+ mice as
described in Materials and Methods. The macrophages were cultured in
the presence or absence of IL-4 (10 ng/ml) as indicated for 48 h. BMM
were stained for Mac3 expression and analyzed by FACS.
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